Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Nuvation Bio (NYSE: NUVB) will host a conference call and webcast on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and provide a business update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuvation Bio (NYSE: NUVB) will host a conference call and webcast on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and provide a business update. The live and archived webcast will be available via the Investor Relations section of its website.
Details
News Market Reaction – NUVB
On Jul 23, the first trading day after this news, NUVB closed 0.92% below the previous close. Argus tracked a trough of -2.0% from its starting point during tracking. Our momentum scanner recorded 7 alerts in the available session data.
Data tracked by StockTitan Argus for the Jul 23 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-461-5787 (
About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.
Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).
Media and Investor Contacts
Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com
Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-6-2026-302830730.html
SOURCE Nuvation Bio, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.